Protection of rhesus macaques against inhalational anthrax with a Bacillus anthracis capsule conjugate vaccine
Protection of rhesus macaques against inhalational anthrax with a Bacillus anthracis capsule conjugate vaccine
复制标题
DOI：
10.1016/j.vaccine.2016.06.031
复制
发表时间：
2016-07-25
期刊：
影响因子：
5.5
通讯作者：
Friedlander, Arthur M.
中科院分区：
文献类型：
--
作者：
Chabot, Donald J.;Ribot, Wilson J.;Friedlander, Arthur M.
目前获得许可的炭疽疫苗的功效主要归功于单一的炭疽芽孢杆菌免疫原，保护性抗原。为了扩大对可能对保护性抗原疫苗产生耐药性的菌株的保护，我们先前开发了一种疫苗，其中炭疽聚谷氨酸胶囊与血清型乙型脑膜炎奈瑟菌的外膜蛋白复合物共价结合，并证明两剂2.5 μ g这种疫苗可部分保护恒河猴免受吸收性炭疽的侵害。在这里，我们证明了恒河猴对吸入性炭疽的完全保护，相同的胶囊结合疫苗的50 μ g剂量更高。这些结果表明，炭疽芽胞杆菌胶囊是一种高效的疫苗成分，应考虑在下一代炭疽疫苗中加入。Elsevier Ltd.出版。
The efficacy of currently licensed anthrax vaccines is largely attributable to a single Bacillus anthracis immunogen, protective antigen. To broaden protection against possible strains resistant to protective antigen-based vaccines, we previously developed a vaccine in which the anthrax polyglutamic acid capsule was covalently conjugated to the outer membrane protein complex of Neisseria meningitidis serotype B and demonstrated that two doses of 2.5 mu g of this vaccine conferred partial protection of rhesus macaques against inhalational anthrax. Here, we demonstrate complete protection of rhesus macaques against inhalational anthrax with a higher 50 mu g dose of the same capsule conjugate vaccine. These results indicate that B. anthracis capsule is a highly effective vaccine component that should be considered for incorporation in future generation anthrax vaccines. Published by Elsevier Ltd.